COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE

1 - 29 . (canceled)

30 . A Method of treatment of bovine respiratory disease or swine respiratory disease comprising administering to an animal a compound according to the formula (I):

or a stereoisomer, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein A is selected from the group consisting of

NR A1 R A2 , and NO 2 ,

wherein

R A1 , R A2 are independently selected from the group consisting of

H, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, aryl, heterocyclyl, heteroaryl, C 1-6 -alkyloxy-C 1 -C 6 , C 1 -C 6 -alkyl substituted with aryl, C 1 -C 6 -alkyl substituted with heteroaryl, C 1 -C 6 -alkyl substituted with heterocyclyl, or

R A1 , R A2 together with the N atom to which they are attached can form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S, and O;

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkyloxy or the heterocyclic ring formed by R A1 , R A2 together with the N atom to which they are attached is optionally substituted with a substituent selected from the group consisting of

C 1-6 -alkyl, C 3-8 -cycloalky, C 1-6 -alkyloxy, —NR A3 R A4 —, carbonyl, —C(═O)—OR A5 —, halogen atom, C 1-6 -alkyl substituted with halo, C 1-6 -alkyloxy-C 1 -C 6 —, aryl, heteroaryl, C 1 -C 6 -alkyl substituted with aryl, cyano, hydroxy, —SR A5 —, —SO 2 R A5 —, SO 2 NR A3 R A4 , —C(═O)NR A3 R A4 —, C 1-6 -alkyl substituted with hydroxy;

wherein

R A3 , R A4 , R A5 are independently chosen from

H, or C 1-6 -alkyl;

L is absent or selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, aryl, heterocyclyl, heteroaryl, —(NR L3 ) 0-1 —(CH 2 ) 0-4 —NR L3 —(CH 2 ) 0-4 —, —(NR L3 ) 0-1 —(CR L1 R L2 ) 0-4 —NR L3 —(CR L1 R L2 )—, —(CR L1 R L2 ) 0-4 —O—(CR L1 R L2 )—, —(CH 2 ) 0-4 —NR L3 —(CR L1 R L2 )—C(═O)NH—(CH 2 ) 0-4 —, —C(═O)—(CR L1 R L2 )—NR L3 C(═O)—, —C(═O)NR L3 —, —NR L3 C(═O)—, —NR L3 —, —SO 2 NR L3 —, NR L3 —C(═O)—NR L3 —

wherein

R L1 , R L2 , R L3 , are independently selected from the group consisting of

H, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 1 -C 6 -alkyl substituted with aryl, C 1 -C 6 -alkyl substituted with heteroaryl, C 1 -C 6 -alkyl substituted with heterocyclyl; or

R L1 , R L3 together with the atoms to which they are attached can form a saturated or unsaturated heterocyclic ring having 3 to 8 ring atoms, wherein 1, 2, or 3, ring atoms are selected from N, S, and O;

M is selected from the group consisting of

C 3-10 -cycloalkyl, aryl, heterocyclyl, heteroaryl, C 2-4 alkenyl, C 2-4 alkynyl, —C(R M1 )═C(R M1 )—C≡C—, —C(R M1 )═C(R M1 )—,

wherein each cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with a substituent selected from the group consisting of

C 1-6 -alkyl, C 3-8 -cycloalky, C 1-6 -alkyloxy, NR M2 R M3 , carbonyl, —C(═O)—OR M2 , halo, halo-C 1-6 -alkyl, C 1-6 -alkyloxy-C 1 -C 6 , aryl, heteroaryl, C 1 -C 6 -alkyl substituted with aryl, cyano, hydroxy, —SR M2 , —SO 2 R M4 , —OSO 2 R M4 , —SO 2 NR M2 R M3 , —C(═O)NR M2 R M3 —, hydroxy-C 1-6 -alkyl;

wherein R M1 is selected from the group consisting of H, C 1-6 -alkyl, halo, hydroxyl, and amino;

wherein R M2 , R M3 are independently selected from the group consisting of H, and C 1-6 -alkyl;

wherein R M4 is selected from the group consisting of H, C 1-6 -alkyl, and amino;

G is selected from the group consisting of

—(C(R G2 R G3 ) 0-4 —O—(C(R G2 R G3 ) 0-4 —, —(C(R G2 R G3 ) 0-4 —S—(C(R G2 R G3 ) 0-4 —, —(C(R G2 R G3 ) 0-4 —NR R1 —(C(R G2 R G3 ) 0-4 —, —C(═O)—, —NR G1 C(═O)—, —C(═O)—, —C(═O)NR G1 —, —(C(R G2 R G3 ) 0-4 —NR G1 —C(R G2 R G3 )—C(═O)NR G1 —, —CR G2 ═CR G2 —, —CR G2 ═CR G2 —CR G2 ═CR G2 —, —C≡C—, —C≡C—C≡C—, —CR G2 ═CR G2 —C≡C—, —C≡C—CR G2 ═CR G2 , —C(═O)—C≡C—, —C≡C—C(═O)— —SO 2 —, —S(═O)—, —S(═O)C(R G2 R G3 )—. —C(R G2 R G3 )S(═O)—, —C(R G2 R G3 )—SO 2 —, —SO 2 C(R G2 R G3 )—;

wherein

R G1 is H or C 1-6 -alkyl

each R G2 , R G3 is independently selected from the group consisting of

H, halogen atom, or C 1-6 -alkyl;

Y is selected from the group consisting of

C 3-10 -cycloalkyl, aryl, heterocyclyl, heteroaryl,

wherein each cycloalkyl, aryl, heterocyclyl, or heteroaryl is optionally substituted with a substituent selected from the group consisting of

C 1-6 -alkyl, C 3-8 -cycloalky, C 1-6 -alkyloxy, NR Y1 R Y2 , carbonyl, —C(═O)—OR Y1 , halo, halo-C 1-6 -alkyl, C 1-6 -alkyloxy-C 1 -C 6 , aryl, heteroaryl, C 1 -C 6 -alkyl substituted with aryl, cyano, hydroxy, —SR Y2 , —SO 2 R Y3 , —OSO 2 R Y3 , —SO 2 NR Y1 R Y2 , —C(═O)NR Y2 R Y3 —, hydroxy-C 1-6 -alkyl;

wherein R Y1 , R Y2 are independently selected from the group consisting of H, and C 1-6 -alkyl;

wherein R Y3 is selected from the group consisting of H, C 1-6 -alkyl, and amino;

X is absent or selected from the group consisting of

—C(═O)—, —C 1-6 -alkyl-C(═O)—, —C 2-6 -alkenyl-C(═O)—, —C 2-6 -alkynyl-C(═O)—, and —(C(R X1 ) 2 —, —S(═O)—, —SO 2 —;

wherein

R X1 . is selected from the group consisting of

H, halogen atom, substituted C 1-6 -alkyl, or un-substituted C 1-6 -alkyl;

wherein the substituents on the substituted C 1-6 -alkyl may be selected from the group consisting of halogen, hydroxyl, alkoxy, aryloxy, thiol, C 1-6 -alkyl, carbonyl, —SR X3 , —SO 2 R X5 , —C(═O)NR X3 R X4 , cyano, —NR X3 R X4 , —C(═O)—OR X3 , aryl, heteroaryl, heterocycle, C 3-8 -cycloalkyl;

wherein R X3 , R X4 are independently selected from the group consisting of H, or C 1-6 -alkyl;

wherein RX 5 is selected from the group consisting of H, C 1-6 -alkyl, and amine;

R 1 is selected from the group consisting of

H, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, C(═O)R 9 , C(═N—OR 8 )R 8 , aryl, heterocyclyl, heteroaryl, C 1 -C 6 -alkyl substituted with aryl, C 1 -C 6 -alkyl substituted with heteroaryl, C 1 -C 6 -alkyl substituted with heterocyclyl;

wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, is optionally substituted with a substituent selected from the group consisting of

C 1-6 -alkyl, C 3-8 -cycloalky, C 1-6 -alkyloxy, NR 6 R 7 , carbonyl, nitro, C(═O)OR 9 , halogen, halo-C 1-6 -alkyl, C 1-6 -alkyloxy-C 1 -C 6 , cyano, hydroxy, —SR 8 , —SO 2 R 8 , SO 2 NR 6 R 7 , —C(═O)NR 6 R 7 —;

wherein R 6 , R 7 , R 8 are independently chosen from H, or C 1-6 -alkyl;

wherein R 9 is selected from the group consisting of H, hydroxyl, or C 1-6 -alkyl;

R 2 , R 3 are independently selected from the group consisting of

H, substituted C 1-6 -alkyl, or un-substituted C 1-6 -alkyl;

wherein the substituents on the substituted C 1-6 -alkyl may be selected from the group consisting of halogen, hydroxyl, alkoxy, aryloxy, thiol, C 1-6 -alkyl, carbonyl, —SR 8 , —SO 2 R 8 , SO 2 NR 6 R 7 , —C(═O)NR 6 R 7 , cyano, —NR 6 R 7 , —C(═O)—OR 6 , aryl, heteroaryl, heterocycle, C 3-8 -cycloalkyl;

q is 0, 1, 2, 3, or 4;

R 4 is selected from the group consisting of

H, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, —OR 8 , C(═O)OR 9 , C(═O)R 9 , aryl, heterocyclyl, heteroaryl, C 1 -C 6 -alkyl substituted with aryl, C 1 -C 6 -alkyl substituted with heteroaryl, C 1 -C 6 -alkyl substituted with heterocyclyl;

wherein each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, is optionally substituted with a substituent selected from the group consisting of

C 1-6 -alkyl, C 3-8 -cycloalky, C 1-6 -alkyloxy, NR 6 R 7 , carbonyl, nitro, C(═O)OR 9 , halogen, halo-C 1-6 -alkyl, C 1-6 -alkyloxy-C 1 -C 6 , cyano, hydroxy, —SR 8 , —SO 2 R 8 , SO 2 NR 6 R 7 , —C(═O)NR 5 R 6 ;

R 5 is selected from the group consisting of H, and C 1-6 -alkyl;

R 6 , R 7 , R 8 are independently selected from the group consisting of H, and C 1-6 -alkyl;

wherein R 9 is selected from the group consisting of H, hydroxyl, or C 1-6 -alkyl.

31 . The method of treatment according to claim 30 wherein A is selected from the group consisting of

NR A1 R A2 , and NO 2 ,

wherein

R A1 , R A2 are independently selected from the group consisting of

H, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, C 1-6 -alkyloxy-C 1 -C 6 , C 1 -C 6 -alkyl substituted with aryl, C 1 -C 6 -alkyl substituted with heteroaryl, C 1 -C 6 -alkyl substituted with heterocyclyl, or

R A1 , R A2 together with the N atom to which they are attached can form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S, and O;

wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, alkyloxy or the heterocyclic ring formed by R A1 , R A2 together with the N atom to which they are attached is optionally substituted with a substituent selected from the group consisting of

C 1-6 -alkyl, C 3-8 -cycloalky, —NR A3 R A4 , carbonyl, halogen atom, C 1-6 -alkyl substituted with halo, aryl, heteroaryl, C 1 -C 6 -alkyl substituted with aryl, cyano, hydroxy, —SR A6 , —SO 2 R A6 , SO 2 NR A3 R A4 , —C(═O)NR A3 R A4 , C 1-6 -alkyl substituted with hydroxy;

wherein

R A3 , R A4 , R A5 are independently chosen from

H, or C 1-6 -alkyl.

32 . The method of treatment according to claim 30 wherein A is NR A1 R A2 .

33 . The method of treatment according to claim 30 , wherein q is 0, or 1.

34 . The method of treatment according to claim 30 , wherein L is selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, —(NR L3 ) 0-1 —(CH 2 ) 0-4 —NR L3 —(CH 2 ) 0-4 —, —(NR L3 ) 0-1 —(CR L1 R L2 ) 0-4 —NR L3 —(CR L1 R L2 )—, —(CR L1 R L2 ) 0-4 —O—(CR L1 R L2 )—, —(CH 2 ) 0-4 —NR L3 —(CR L1 R L2 )—C(═O)NH—(CH 2 ) 0-4 —, —C(═O)—(CR L1 RL 2 )—NR L3 C(═O)—, —C(═O)NR L3 —, —NR L3 C(═O)—, —NR L3 —, —SO 2 NR L3 —, NR L3 —C(═O)—NR l3 —;

wherein

R L1 , R L2 , R L3 , are independently selected from the group consisting of

H, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 1 -C 6 -alkyl substituted with aryl, C 1 -C 6 -alkyl substituted with heteroaryl, C 1 -C 6 -alkyl substituted with heterocyclyl; or

R L1 , R L3 together with the atoms to which they are attached can form a saturated or unsaturated heterocyclic ring having 3 to 8 ring atoms, wherein 1, 2, or 3, ring atoms are selected from N, S, and O.

35 . The method of treatment according to claim 30 , wherein L is selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, —NR L3 —;

wherein

R L3 is selected from the group consisting of

H, C 1-6 -alkyl, halo-C 1-6 -alkyl, C 1 -C 6 -alkyl substituted with aryl, C 1 -C 6 -alkyl substituted with heteroaryl, C 1 -C 6 -alkyl substituted with heterocyclyl.

36 . The method of treatment according to claim 30 , wherein L is selected from the group consisting of —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, and —CH 2 CH 2 CH 2 CH 2 —.

37 . The method of treatment according to claim 30 , wherein M is selected from the group consisting of

C 3-10 -cycloalkyl, aryl, heterocyclyl, heteroaryl, C 2-4 alkenyl, C 2-4 alkynyl, —C(R M1 )═C(R M1 )—C≡C—, —C(R M1 )═C(R M1 )—.

38 . The method of treatment according to claim 30 , wherein G is selected from the group consisting of

—CR G2 ═CR G2 —, —CR G2 ═CR G2 —CR G2 ═CR G2 —, —C≡C—, —C≡C—C≡C—, —CR G2 ═CR G2 —C≡C—, —C≡C—CR G2 ═CR G2 , —C(═O)—C≡C—, —C≡C—C(═O)—;

wherein

R G2 is selected from the group consisting of

H, halogen atom, or C 1-6 -alkyl.

39 . The method of treatment according to claim 30 , wherein the compound is a compound according to formula (IX)

or a stereoisomer, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein A, L, M, Y, X, q, R 1 , R 2 , R 3 , R 4 , and R 5 , are defined as in claim 30 .

40 . The method of treatment according to claim 30 , wherein Y is selected from aryl, or heteroaryl.

41 . The method of treatment according to claim 30 , wherein the compound is a compound according to formula (XI)

or a stereoisomer, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein A, L, M, X, q, R 1 , R 2 , R 3 , R 4 , and R 5 , are defined as in claim 30 .

42 . The method of treatment according to claim 30 , wherein X is selected from the group consisting of —C(═O)—, and —S(═O).

43 . The method of treatment according to claim 30 , wherein the compound is a compound according to formula (XVI)

or a stereoisomer, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein A, L, M, G, Y, q, R 1 , R 2 , R 3 , R 4 , and R 5 , are defined as in claim 30 .

44 . The method of treatment according to claim 30 , wherein R 2 , R 3 is independently selected from the group consisting of H, substituted C 1-6 -alkyl, or un-substituted C 1-6 -alkyl, wherein the substituent on the substituted C 1-6 -alkyl is selected from the group consisting of halogen, hydroxyl, C 1-6 -alkyl, carbonyl, —SR 8 , —SO 2 R 8 , SO 2 NR 6 R 7 , —C(═O)NR 6 R 7 , cyano, —NR 6 R 7 , —C(═O)—OR 6 .

45 . The method of treatment according to claim 30 , wherein R 4 is selected from the group consisting of H, C 1-6 -alkyl, —OR 8 , —C(═O)OR 9 , C(═O)R 9 .

46 . The method of treatment according to claim 30 , wherein R 1 is selected from the group consisting of C 1-6 -alkyl, C(═O)R 9 , C(═N—OR 8 )R 8 , wherein the alkyl is optionally substituted with a substituent selected from the group consisting of C 1-6 -alkyl, —NR 6 R 7 , carbonyl, nitro, C(═O)OR 9 , halogen, cyano, hydroxy, —SR 8 , —SO 2 R 8 , SO 2 NR 6 R 7 , —C(═O)NR 6 R 7 —.

47 . The method of treatment according to claim 30 , wherein the compound is a compound according to formula

or a stereoisomer, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein A, L, M, G, Y, and X, are defined as in claim 30 .

48 . The method of treatment according to claim 30 , wherein the compound is a compound according to formula

or a stereoisomer, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein A, L, M, G, Y, and X, are defined as in claim 30 .

49 . The method of treatment according to claim 30 , wherein the compound is a compound according to formula

or a stereoisomer, pharmaceutically acceptable salt, ester, solvate, or prodrug thereof, wherein A, L, M, G, Y, and X, are defined as in claim 30 .

50 . The method of treatment according to claim 30 wherein the treatment is prevention of bovine respiratory disease.

51 . The method of treatment according to claim 30 wherein the treatment is prevention of swine respiratory disease.

52 . The method of treatment according to claim 30 wherein an effective dose is between about 0.01 to about 50 mg/kg bodyweight of the animal.

53 . The method of treatment according to claim 30 wherein one or two doses of the compound in a pharmaceutically acceptable carrier are administered to the animal.

54 . The method of treatment according to claim 30 wherein a composition comprising the compound and a veterinarily acceptable carrier is administered subcutaneously.